Urinary Tract Infections Market: Information By Drug Class (Quinolones (Ciprofloxacin, Enoxacin, Norfloxacin, Ofloxacin, Pefloxacin, Fleroxacin), Β-Lactam & Cephalosporins (Amoxicillin-Clavulanate, Cefdinir, Cefaclor, Cefpodoxime-Proxetil), Aminoglycosides, Penicillin, Azoles), Application (Urethritis, Cystitis, Pyelonephritis), Pathogen (Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis), End-User (Hospitals, Clinics, Self-Administered) and Region (Americas, Europe,...

Urinary Tract Infection Market Overview

A person having diabetes and further, contracting the urological health issues have a very close connection. Diabetes further creates health issues and increases the risk of contracting UTIs, alongside bladder issues. Also, diabetes can lead and result in a worsened condition of the problems like urologic issues and conditions. This is because, these are known to have an impact on the blood flow of an individual, the functions of the nerves and also affect the sensory functions that are performed by the body. A huge population that lives in different parts of the world is affected by diabetes health conditions. Also, this is further giving a rise to other commonly occurring issues like kidney stones and also, increased number of UTI cases being reported with each passing day. The patients who are suffering from similar illnesses are demanding treatment and drugs at a global scale and hence, this is likely to give a prominent rise to the urinary tract infection market by the end of the global forecast period in 2027. 

Owing to these trends, increased infections, and the demand for drugs and treatment, the market report reflects a promising and increasing future for the market size. The urinary tract infection market is expected to rise at a 3.5% CAGR and thus, reach a market valuation worth USD 11.3 billion by the end of the global forecast period in 2027.

COVID 19 Analysis

Since the novel coronavirus is expanding its horizon and entering various industries, market verticals, businesses, and countries, researchers are on the way to have more knowledge and vaccine development for the treatment of different infection variants. Due to the adversity of the situation, the people are questioning the competence of the prevailing healthcare structure and thus, are demanding a well-equipped, updated, and technology-related infrastructure. Also, the spread of the pandemic has been very bad for the production and manufacturing units of businesses and companies. They have been forced to shut down because of their incapacity and incapability to live up to the urinary tract infection industry demands and production levels. Healthcare services, on the other hand, are experiencing a rise.

However, the healthcare professionals are employed in treating the patients who have contracted the coronavirus diseases, the ones who are suffering from other issues like diabetes and UTIs are having a hard time. So, the government is collaborating with the key market players regarding the investment decisions in the development of infrastructure that is based on high technology and also, caters to the demands in qualitative and efficient ways.

Urinary Tract Infection Market Dynamics

Drivers

The key urinary tract infection market players are investing in the research and development departments for combining and launching more drugs that suit the needs of a global audience. For instance, FDA has superiority as a combination for treating patients who are suffering from a kidney infection. Hence, these will help the urinary tract infection market to grow as per the expectation during the forecast period.

Restraints

Currently, the process of designing the antibacterial drugs and trials is an elaborated and complex procedure. Also, the absence of an ethical and scientific approach during these procedures is likely to restrain the market from growing as per the expectation during the assessment period.

Technology Analysis

The urinary tract infection market is opting for clinical trials for antibodies that belong to the therapeutic drugs categories. With due respect to the approach and the results presented after conducting the procedures, like trial design, interpretation, alongside the elaborated analysis. To approve the trials, it is better to design the drugs in a simple way that targets the enhancement of passing informative and ethical use. Also, the market players are likely to follow a scientific approach and developing steps to cater to similar requirements. Hence, the urinary tract infection market has a promising global forecast period that ends in 2027.

Study Objectives

• To have an overview of the market, study the impact of the pandemic on the market operations and further, discuss the dynamics like drivers, opportunities, and restraints that are available to the market for growth during the forecast period


• To study and analyze the market operations and the performance of the segments in major geographies of the world. These give the revenue insight and also help investors take investment and marketing decisions


• To analyze the degree of competition prevailing in the market by having an idea about the key market players and the strategies for growth undertaken by them through the recent developments during the forecast period that ends in 2027

 Urinary Tract Infections Market Share, By Type, 2019 (%)

Source: MRFR Analysis

Urinary Tract Infection Market Segment Overview

To discuss the urinary tract infection market growth, it is imperative to have an idea about the revenue cycle of the global market. The market has been bifurcated into segments that will help to understand the operations and revenue potential. This makes a difference to the investment decisions and market strategies taken up. The global market has been segmented based on the following heads:

Drug class

The urinary tract infection deals in drugs like quinolones, aminoglycosides, azoles, alongside others like penicillin, and cephalosporins. Quinolones are further being segmented into enoxacin, pefloxacin, norfloxacin, alongside fleroxacin. In 2019, this was the highest growing sub-segment in the market.

Application

The applications segment of the urinary tract infection includes cystitis, pyelonephritis, alongside urethritis, amongst others. Urethritis experienced the largest market share back in 2019.

Pathogen

This segment includes escherichia coli, klebsiella pneumonia, Proteus mirabilis, and others

Market end-users

Hospitals, healthcare centers, clinics, alongside the self-administered ones, are the market end-users of the urinary tract infection market.

Global Urinary Tract Infections Market Share, By Region, 2019 (%)

Source: MRFR Analysis

Regional Analysis

The North American market consisting of countries like the USA, and Canada, alongside Latin America. The North American market is expecting a steep increase in their investment towards innovation and technological advancements towards therapeutic products and diagnoses that will be helpful for the global growth of the urinary tract infection market. The USA has an increasingly global market share owing to the demand because of the rising prevalence of UTIs and kidney problems amongst the population of this region. The second-largest regional growth in terms of revenue is likely to be experienced by the European nations. The economic burden associated with the market is increasing in Europe. However, the fastest growth during the tenure is likely to be experienced by the APAC urinary tract infection market as the awareness is rising and people are getting education related to the same.

Competitive Landscape

To draw a competitive graph amongst the key market players of the market and assess the revenue potential through the recent developments undertaken, it is important to have an idea of the functional urinary tract infection market players. They are as follows:

• Pfizer Inc.


• Teva Pharmaceuticals


• Novo Nordisk A/S


• GlaxoSmithKline plc


• Bayer AG


• Novartis Ag


• Cipla Inc.


• Merck & Co., Inc.


• Eli Lily


• Company, Allergan

Recent Developments

• The International Diabetes Federation released its data and statistics related to the diabetic population. As per the released data, approximately 463 million adults across the world that is those who fall under the age group of 20-79 years, and owing to the sedentary lifestyle that the people follow, the figures are going to increase with an expectation to reach as many as 700 million by the end if 2045. Hence, the US market players are investing in developing infrastructure and medicine that reduces the risks of diabetic patients contracting urinary infections.


• Also, low-income countries like the Middle East and African nations, are increasing in the population of people who are suffering from diabetes. To help these companies with the required healthcare services and infrastructure, these market players are opening their horizons towards global acquisitions and mergers that will benefit the patients that are a part of this region and help the market take its initial steps towards growth for the current market period that ends in 2027.


• In a released press release, the FDA stated that a drug named Vabomere enjoys statistical superiority over the other drug combinations and hence, this combination is likely to help a major chunk of the population that is suffering from UTI issues during the forecast period that ends in 2027.


• The African market players are aiming a steady growth because of the increased level of exposure in the regions for environmental toxins that bring forward disease burdens and the risks of contracting non-communicable diseases also. Hence, the market is coming up with solutions and remedies that will help the market grow in the future.

Intended Audience

• Orphan drug stores and companies


• Hospitals and healthcare centers


• Clinics ‘diagnostic labs


• UTI drug manufacturers and the urinary tract infections drug suppliers across the globe

Report Overview

The global market report has been curated by considering the viewpoints as put forward by the industry experts and market leaders. Also, the report helps to have an idea about the market dynamics and insights of the market for better decisions. The report mentions the market segregation across various geographical regions and also, discusses the prominent urinary tract infection market players. The report also mentions the market’s recent developments.